康諾亞-B(02162.HK)與Belenos訂立有關CM512及CM536的獨家許可協議
格隆匯7月9日丨康諾亞-B(02162.HK)發佈公吿,2024年7月9日,康諾亞生物醫藥科技(成都)有限公司(“成都康諾亞”,集團的全資附屬公司)與Belenos Biosciences, Inc.(“Belenos”)已訂立許可協議。許可協議授予Belenos在全球(不包括大中華地區)開發、生產及商業化集團候選藥物CM512及CM536的獨家權利。CM512及CM536均為康諾亞自主開發的雙特異性抗體。
在許可協議的條款及條件規限下,Belenos獲授CM512及CM536在許可地區的研究、開發、註冊、生產及商業化的獨家許可。作為對價,成都康諾亞將收取15百萬美元的首付款和近期付款,而一橋香港控股有限公司(“一橋香港”,集團的全資附屬公司)將收取Belenos約30.01%的股權。在達成若干開發、監管及商業里程碑後,成都康諾亞亦可收取最多1.70億美元的額外付款。於CM512及CM536 首次商業銷售後開始的指定時間段內,成都康諾亞亦有權從Belenos收取銷售淨額的分層特許權使用費。除另有協定外,Belenos將負責承擔CM512及CM536在許可地區的所有開發、監管及商業化活動的成本。
就許可協議而言,Belenos與成都康諾亞將訂立供應協議,據此,Belenos將有權向成都康諾亞或其合同生產商採購所需數量的CM512及CM536以便進行該等臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.